No impact of body mass index on outcome in stroke patients treated with IV thrombolysis BMI and IV thrombolysis outcome by Branscheidt, M et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
No impact of body mass index on outcome in stroke patients treated with
IV thrombolysis BMI and IV thrombolysis outcome
Branscheidt, M; Schneider, J; Michel, P; Eskioglou, E; Kaegi, G; Stark, R; Fischer, U; Jung, S; Arnold,
M; Wertli, M; Held, U; Wegener, S; Luft, A; Sarikaya, H
Abstract: BACKGROUND AND PURPOSE The impact of excess body weight on prognosis after stroke
is controversial. Many studies report higher survival rates in obese patients (”obesity paradox”). Recently,
obesity has been linked to worse outcomes after intravenous (IV) thrombolysis, but the number and
sample size of these studies were small. Here, we aimed to assess the relationship between body weight and
stroke outcome after IV thrombolysis in a large cohort study. METHODS In a prospective observational
multicenter study, we analyzed baseline and outcome data of 896 ischemic stroke patients who underwent
IV thrombolysis. Patients were categorized according to body mass index (BMI) as underweight (<18.5
kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), obese (30-34.9 kg/m2) or severely
obese (>35 kg/m2). Using uni- and multivariate modeling, we assessed the relationship of BMI with
favorable outcome (defined as modified Rankin Scale 0 or 1) and mortality 3 months after stroke as well
as the occurrence of symptomatic intracerebral hemorrhages (sICH). We also measured the incidence
of patients that had an early neurological improvement of >40% on the National Institutes of Health
Stroke Scale (NIHSS) after 24 hours. RESULTS Among 896 patients, 321 were normal weight (35.8%),
22 underweight (2.5%), 378 overweight (42.2%), 123 obese (13.7%) and 52 severely obese (5.8%). Three-
month mortality was comparable in obese vs. non-obese patients (8.1% vs. 8.3%) and did not differ
significantly among different BMI groups. This was also true for favorable clinical outcome, risk of sICH
and early neurological improvement on NIHSS at 24 hours. These results remained unchanged after
adjusting for potential confounding factors in the multivariate analyses. CONCLUSION BMI was not
related to clinical outcomes in stroke patients treated with IVT. Our data suggest that the current weight-
adapted dosage scheme of IV alteplase is appropriate for different body weight groups, and challenge the
existence of the obesity paradox after stroke.
DOI: 10.1371/journal.pone.0164413
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-127650
Accepted Version
Originally published at:
Branscheidt, M; Schneider, J; Michel, P; Eskioglou, E; Kaegi, G; Stark, R; Fischer, U; Jung, S; Arnold,
M; Wertli, M; Held, U; Wegener, S; Luft, A; Sarikaya, H (2016). No impact of body mass index on
outcome in stroke patients treated with IV thrombolysis BMI and IV thrombolysis outcome. PLoS ONE,
11(10):e0164413. DOI: 10.1371/journal.pone.0164413
  1 
No Impact of Body Mass Index on Outcome in Stroke Patients  1 
Treated with IV Thrombolysis 2 
BMI and IV Thrombolysis Outcome 3 
 4 
Meret Branscheidt1,2, Juliane Schneider1, Patrik Michel3, Elissavet Eskioglou3, Georg Kaegi4, Robert 5 
Stark4, Urs Fischer5, Simon Jung5, Marcel Arnold5, Maria Wertli6,7, Ulrike Held6, Susanne Wegener1, 6 
Andreas Luft1, Hakan Sarikaya1,5* 7 
1Department of Neurology, University Hospital of Zurich, Switzerland 8 
2Department of Physical Medicine and Rehabilitation, Johns Hopkins University, Baltimore, Maryland, United 9 
States of America 10 
3Department of Neurology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Switzerland 11 
4Department of Neurology, Kantonsspital St. Gallen, Switzerland 12 
5Department of Neurology, University Hospital Bern, Switzerland 13 
6Horten Centre, University of Zurich, Switzerland 14 
7Department of Internal Medicine, University Hospital Bern, Switzerland 15 
 16 
* Corresponding author  17 
Email: hakan.sarikaya@insel.ch (HS) 18 
 19 
 20 
	21 
	22 
	23 
	24 
 25 
  2 
Abstract  26 
Background and Purpose  27 
The impact of excess body weight on prognosis after stroke is controversial. Many studies report 28 
higher survival rates in obese patients (“obesity paradox”). Recently, obesity has been linked to worse 29 
outcomes after intravenous (IV) thrombolysis, but the number and sample size of these studies were small. 30 
Here, we aimed to assess the relationship between body weight and stroke outcome after IV thrombolysis 31 
in a large cohort study. 32 
Methods 33 
In a prospective observational multicenter study we analyzed baseline and outcome data of 896 34 
ischemic stroke patients who underwent IV thrombolysis. Patients were categorized according to body mass 35 
index (BMI) as underweight (<18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), 36 
obese (30-34.9 kg/m2) or severely obese (>35 kg/m2). Using uni- and multivariate modeling, we assessed 37 
the relationship of BMI with favorable outcome (defined as modified Rankin Scale 0 or 1) and mortality 3 38 
months after stroke as well as the occurrence of symptomatic intracerebral hemorrhages (sICH). We also 39 
measured the incidence of patients that had an early neurological improvement of >40% on the National 40 
Institutes of Health Stroke Scale (NIHSS) after 24 hours. 41 
Results  42 
Among 896 patients, 321 were normal weight (35.8%), 22 underweight (2.5%), 378 overweight 43 
(42.2%), 123 obese (13.7%) and 52 severely obese (5.8%). Three-month mortality was comparable in obese 44 
vs. non-obese patients (8.1% vs. 8.3%) and did not differ significantly among different BMI groups. This 45 
was also true for favorable clinical outcome, risk of sICH and early neurological improvement on NIHSS 46 
at 24 hours. These results remained unchanged after adjusting for potential confounding factors in the 47 
multivariate analyses. 48 
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Conclusion  49 
BMI was not related to clinical outcomes in stroke patients treated with IVT. Our data suggest that 50 
the current weight-adapted dosage scheme of IV alteplase is appropriate for different body weight groups, 51 
and challenge the existence of the obesity paradox after stroke.  52 
 53 
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Introduction  74 
Stroke and obesity are both characterized by increasing incidence worldwide, causing huge socio-75 
economic costs [1]. While obesity is an established risk factor for stroke occurrence, its impact on outcome 76 
after stroke is controversial. Many studies suggest survival benefit and better clinical outcome in obese 77 
stroke patients as compared to their normal weight counterparts [2–4]. This observation has already been 78 
described in many other conditions such as heart failure, and is termed as “obesity paradox” [4]. The 79 
relationship between obesity and stroke outcome after intravenous thrombolysis (IVT) is less clear due to 80 
scarce number of studies with small sample size and contradictory results. This issue is of clinical relevance, 81 
as obesity especially affects younger people with increase of stroke risk and thus higher probability for 82 
IVT. Therefore, we aimed to investigate clinical outcomes after IVT in a large cohort of patients with acute 83 
ischemic stroke (AIS) according to body mass index (BMI). 84 
 85 
Methods  86 
As a joint initiative of four Swiss stroke centers (Berne, Zurich, Lausanne, St. Gallen), we performed 87 
a large prospective multicenter study to determine the impact of body weight on stroke outcome after IVT 88 
(data collection from 2003 to 2014). Patients needed to meet the following two criteria for study inclusion: 89 
1. Treatment with IVT (alteplase) for AIS according to the current guidelines of the European Stroke 90 
Organization [5], 2. Availability of body mass index (BMI) at baseline and outcome data at 3 months. Data 91 
from individual patients were systematically and prospectively collected in each center by using a 92 
standardized form with pre-defined variables as applied in previous studies [6]. Compilation of completed 93 
forms from all centers and analyses of the pooled data were performed in the coordinating center in Berne, 94 
Switzerland. Detailed data on the number of consecutive patients and study period for each center are 95 
available as supplemental material. The study was approved by local ethics committees of the individual 96 
study centers in Berne (Kantonale Ethikkomission Bern Nr. 231/2014), St. Gallen (Kantonale 97 
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Ethikkomission St. Gallen Nr. 280/09), Zurich (Kantonale Ethikkomission Zürich Nr. 2013-0105) and 98 
Lausanne (Kantonale Ethikkommision Waadt Nr. 40/07). Patients records were recorded and de-identified 99 
prior to analysis. According to the approvals, we did not need informed consent from individuals for 100 
retrospective data. All clinical investigations were conducted according to the principles expressed in the 101 
Declaration of Helsinki.  102 
The following variables were prospectively collected in all participating centers: age, sex, vascular risk 103 
factors according to predefined criteria [7], history of coronary artery disease, antithrombotic medication 104 
at stroke onset, initial stroke severity as assessed by the National Institutes of Health Stroke Scale (NIHSS) 105 
score [8], stroke etiology according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria 106 
[9], stroke onset-to-treatment time as well as blood pressure and blood glucose level obtained at admission. 107 
All patients treated with IVT were admitted to intermediate or intensive care units for at least 24 hours. All 108 
patients underwent brain imaging with computed tomography or magnetic resonance imaging 24 to 48 109 
hours after IVT and in any case of clinical deterioration. 110 
 111 
Body mass index assessment  112 
Body mass index (BMI) was calculated as weight in kilograms divided by height squared in meters. 113 
Body weight and height were either measured by nurses or - if not applicable - estimated by the attending 114 
stroke physician during the hospital stay. For obesity measures, we adopted the following BMI threshold 115 
categories from World Health Organization (WHO): <18.5 kg/m2 for underweight, 18.5 to 24.9 kg/m2 for 116 
normal weight, 25.0 to 29.9 kg/m2 for overweight, 30.0 to 34.9 kg/m2 for obesity and ≥35 kg/m2 for severe 117 
obesity [10].  118 
 119 
Assessment of outcomes  120 
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Clinical outcomes were assessed during outpatient visits using the modified Rankin Scale (mRS) 121 
score at 3 months [11]. Main outcome measures in this study were (i) favorable outcome (defined as mRS 122 
0 or 1), (ii) good outcome (defined as mRS 0 to 2), (iii) death within 3 months and (iv) symptomatic 123 
intracerebral hemorrhage (sICH) according to the definition of the Safe Implementation of Thrombolysis 124 
in Stroke-Monitoring Study (SITS-MOST) [12]. In addition, we also used the early neurological 125 
improvement by >40% on NIHSS at 24 hours after IVT as a marker of early arterial recanalization [13]. 126 
 127 
Statistical analyses 128 
Descriptive statistics are presented as median and interquartile range (IQR) for the continuous 129 
parameters, and number and percentages of total for the categorical variables if not stated differently. 130 
Outcome measures were compared with BMI as a categorical variable and as a continuous variable. The 131 
category with normal body weight (BMI 18.5 to 24.9 kg/m2) served as reference group. We compared 132 
demographic and baseline characteristics among different BMI categories by using Fisher exact test or the 133 
chi-square test for categorical variables and the Mann-Whitney U test for continuous variables. Univariate 134 
analysis of the effect of BMI categories on different outcomes was assessed with logistic regression models, 135 
results were presented as estimated odds ratios and corresponding 95% confidence intervals (95% CI). 136 
Besides the univariate analysis, adjusted effects of BMI categories on different outcomes were of interest. 137 
For the adjustment, the following set of potential confounders was identified a-priori according to the 138 
current literature [7]: age, gender, baseline NIHSS score, smoking, history of hypertension, systolic blood 139 
pressure at presentation, history of cardiovascular disease, history of diabetes, blood glucose at admission, 140 
dyslipidemia, antithrombotic treatment at stroke onset, atrial fibrillation and symptom onset-to-treatment 141 
time.  142 
In order to find those variables among the set of potential confounders that influenced the individual 143 
outcome, pairwise correlations between the potential confounder and the outcome were assessed. In the 144 
final multiple models each confounder with a statistically significant relationship with the outcome was 145 
  7 
included, in addition to the determinant BMI category [14]. Finally, the interaction of the confounders with 146 
the BMI subgroups was tested for significance. 147 
Complete data sets were available for BMI. However, there were missing values in the confounders. 148 
Multiple imputation using chained equations and five replications (m=5) were used for each outcome and 149 
corresponding regression analysis. Rubin’s formula was used for the combination of effect estimates and 150 
their standard errors from the multiply imputed datasets. We additionally evaluated each confounder for 151 
the presence of an interaction term with BMI. The interaction was deleted from the model, if it was not 152 
significantly different from zero. Statistical analyses were conducted by using the statistical software R (R 153 
Core Team (2015)). R: A language and environment for statistical computing. R Foundation for Statistical 154 
Computing, Vienna, Austria. URL https://www.R-project.org) and the R-package “mice” [15]. The level 155 
of statistical significance was set to 0.05. 156 
 157 
Results 158 
A total of 896 patients were eligible for this study. Of these, 321 were of normal weight (35.8%, 159 
median BMI 23 kg/m2), 22 were underweight (2.5%, median BMI 17.7 kg/m2), 378 overweight (42.2%, 160 
median BMI 27 kg/m2), 123 obese (13.7%, median BMI 31 kg/m2) and 52 severely obese (5.8%, median 161 
BMI 37 kg/m2). The main baseline characteristics of the study population are detailed in Table S1 162 
(Supporting information).  163 
Gender was differently distributed among BMI categories with a higher percentage of females in the 164 
underweight group (72.7%) as compared to patients with normal weight (46.4%), overweight (33.3%) or 165 
obesity (40.0%). In obese and severely obese patients, the prevalence of arterial hypertension, diabetes 166 
mellitus, blood glucose at admission and use of antithrombotics at stroke onset were significantly higher as 167 
compared to the normal weight group, whereas the baseline NIHSS score tended to be slightly lower. Age 168 
and other baseline characteristics were similar in all BMI groups S1 Table (see Supporting information). 169 
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At 3 months, patients with a BMI <30 kg/m2 (non-obese) showed no significant difference for any of the 170 
outcome measures in comparison to those with a BMI ≥30 kg/m2 (obese), even after adjusting for 171 
confounding variables (Table 1). The adjusted analysis for sICH was identical to the univariate analysis 172 
because none of the potential confounders was significantly associated with sICH.  173 
 174 
Table 1: Comparison of Outcomes in patients with BMI ≥30 kg/m2 vs. <30 kg/m2 175 
Outcome measures 
Unadjusted analysis  Adjusted analysis† 
BMI ≥30 
kg/m2 
BMI <30 
kg/m2  OR [95% CI] 
p 
value  OR [95% CI] 
p 
value 
Favorable outcome  
(mRS 0‐1) 
76/161 
(47.2%) 
278/660 
(42.1%) 
1.229 
 [0.869‐1.736]  0.243 
1.392  
[0.926‐2.093]  0.105 
Good outcome  
(mRS 0‐2) 
101/161 
(62.7%) 
435/660 
(65.9%) 
0.871 
 [0.609‐1.245]  0.448 
0.845 
 [0.556‐1.286]  0.423 
Mortality  13/161 (8.1%) 
55/660 
(8.3%) 
0.966 
 [0.514‐1.815]  0.915 
1.065 
 [0.503‐2.255]  0.866 
sICH   6/170 (3.5%)  18/698 (2.6%) 
1.382  
[0.540‐3.537]  0.500 
1.382 
 [0.540‐3.537]  0.500 
Early NIHSS 
improvement 
84/156 
(53.8%) 
324/648 
(50.0%) 
1.167  
[0.822‐1.656]  0.389 
1.270  
[0.876‐1.843]  0.199 
 176 
Compared to the patients with BMI >30 kg/m2, patients with BMI <30 kg/m2 did not differ in mortality, 177 
early NIHSS improvement, favorable or good functional outcome, or risk for sICH. These results did not 178 
change after adjusting for known confounders: age, gender, baseline NIHSS score, blood glucose at 179 
admission, systolic blood pressure at admission, smoking, presence of arterial hypertension, presence of 180 
diabetes, dyslipidemia, history of cardiovascular disease, antithrombotic treatment at stroke onset, atrial 181 
fibrillation and symptom onset-to-treatment time. Results are presented as odds ratio with 95% confidence 182 
intervals. Abbreviations: BMI (body mass index), OR (odds ratio), CI (confidence interval), IQR (inter 183 
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quartile range), mRS (modified Rankin Scale), sICH (symptomatic intracerebral hemorrhage), NIHSS 184 
(National Institute of Health Stroke Scale). 185 
As compared to the normal weight reference group, none of the BMI categories significantly differed with 186 
respect to the outcomes clinical recovery, mortality, occurrence of sICH, or early NIHSS improvement 187 
(Table 2). In univariate analyses, the following variables were associated with clinical endpoints (favorable 188 
outcome, good outcome, mortality): age, stroke severity measured by baseline NIHSS score, diabetes 189 
mellitus and baseline blood glucose. In addition, mortality was associated with the presence of atrial 190 
fibrillation. Predictors of early NIHSS improvement in univariate analysis were age, diabetes mellitus, 191 
baseline blood glucose and systolic blood pressure at admission. For sICH no model could be fitted due to 192 
singularity because no sICH was observed in the group of underweight and severely obese patients.  193 
 194 
Table 2: Univariate outcome analyses according to BMI categories. 195 
Outcome 
measures 
BMI categories 
n/N (%) 
 OR [95% CI] 
 
 
Normal 
weight* 
(n=321) 
 
Underweight 
(n=22) 
 
Overweight 
(n=378) 
 
Obesity 
(n=123) 
 
Severe Obesity 
(n=52) 
Favourable 
outcome (mRS 0‐
1) a 
114/291 
(39.2%) 
12/21 (57.1%)  
2.070 
 [0.845‐5.070] 
152/348 (43.7%)  
1.204  
[0.877‐1.653] 
56/114 (49.1%) 
1.499  
[0.969‐2.319] 
20/47 (42.6%)  
1.150  
[0.616‐2.147] 
Good outcome 
(mRS 0‐2) b 
194/291 
(66.7%) 
14/21 (66.7%) 
1.000  
[0.391‐2.559] 
227/348 (65.2%) 
0.938  
[0.675‐1.303] 
75/114 (65.8%) 
0.962 
 [0.609‐1.519] 
26/47 (55.3%)  
0.619  
[0.331‐1.156] 
Mortality c  23/291 (7.9%) 
1/21 (4.8%) 
0.583 
 [0.075‐4.539]  
31/348 (8.9%)  
1.139 
 [0.649‐2.002]  
8/114 (7.0%) 
0.879  
[0.381‐2.028]  
5/47 (10.6%) 
1.387  
[0.500‐3.848] 
sICH  11/309 (3.6%) 
0/22 (0%)  
n.a.  
7/367 (1.9%)  
0.527 
 [0.202‐1.376] 
6/120 (5.0%) 
1.426  
[0.515‐3.946]  
0/50 (0%) 
n.a.  
Early NIHSS 
improvement d 
135/283 
(47.7%) 
11/21 (52.4%)  
1.206  
[0.496‐2.930]  
178/344 (51.7%) 
1.176 
 [0.858‐1.611] 
59/106 (55.7%) 
1.376 
 [0.879‐2.155]  
25/50 (50.0%) 
1.096 
 [0.601‐2.000] 
 196 
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Univariate analyses showed no association between different BMI categories and functional outcome, 197 
mortality or the occurrence of sICH. BMI categories set in reference to normal weight patients and were 198 
defined as follows: <18.5 kg/m2 for underweight, 18.5 to 24.9 kg/m2 for normal weight, 25.0 to 29.9 kg/m2 199 
for overweight, 30.0 to 34.9 kg/m2 for obesity and ≥35 kg/m2 for severe obesity. Results are presented as 200 
odds ratio with 95% confidence intervals. (*) Asterix labels the normal weight reference group. Letters a–d 201 
denote significant associations in univariate analysis (see footnotes). Abbreviations: BMI (body mass 202 
index), OR (odds ratio), CI (confidence interval), mRS (modified Rankin Scale), sICH (symptomatic 203 
intracerebral hemorrhage), NIHSS (National Institute of Health Stroke Scale), n.a. (not applicable). 204 
a age, baseline NIHSS, diabetes mellitus, gender, blood glucose, atrial fibrillation; b age, baseline NIHSS, 205 
diabetes mellitus, gender, blood glucose; c age, baseline NIHSS, diabetes mellitus, blood glucose, atrial 206 
fibrillation, coronary heart disease, antithrombotic use at baseline; d age, diabetes mellitus, systolic blood 207 
pressure, blood glucose. 208 
 209 
After multivariate analyses, the outcomes still did not differ among BMI categories as compared to the 210 
normal weight group (Table 3). Although underweight patients showed a trend towards a favorable outcome 211 
(mRS 0-1), one has to consider the broad confidence intervals. Age, stroke severity and baseline blood 212 
glucose were independent predictors of clinical recovery and mortality, whereas systolic blood pressure 213 
and blood glucose at admission were significantly associated with early NIHSS improvement.  214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
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Table 3: Multivariate outcome analyses according to BMI categories. 222 
Outcome 
measures 
BMI categories 
 OR [95% CI] 
 
Underweight 
vs. 
normal weight 
Overweight 
vs. 
normal weight 
Obesity 
vs. 
normal weight 
Severe Obesity 
vs. 
normal weight 
Favorable 
outcome (mRS 
0‐1) a 
2.847 [1.000‐8.112]  1.094 [0.756‐1.583]  1.569 [0.942‐2.614]  1.375 [0.660‐2.867] 
Good outcome 
(mRS 0‐2) b  1.084 [0.361‐3.256]   0.791 [0.537‐1.166]   0.856 [0.503‐1.459]  0.549 [0.263‐1.144] 
Mortality c  0.441 [0.046‐4.270]  1.341 [0.684‐2.629]  1.081 [0.400‐2.919]  1.605 [0.469‐5.486] 
Early NIHSS 
improvement d  1.120 [0.445‐2.820]  1.160 [0.835‐1.611]  1.419 [0.886‐2.273]   1.301 [0.685‐2.473] 
 223 
The multivariate analyses showed no differences between overweight, obese and severely obese patients in 224 
reference to normal weight patients regarding functional outcome, mortality or sICH. Results are presented 225 
as odds ratio with 95% confidence intervals. Letters a–d denote significant associations in multivariate 226 
analysis. Abbreviations: BMI (body mass index), OR (odds ratio), CI (confidence interval), mRS (modified 227 
Rankin Scale), sICH (symptomatic intracerebral hemorrhage), NIHSS (National Institute of Health Stroke 228 
Scale). 229 
a baseline NIHSS (p<0.001), age (p=0.008), blood glucose (p=0.008); b age (p<0.001), baseline NIHSS 230 
(p<0.001); c age (p<0.001), baseline NIHSS (p<0.001), blood glucose (p=0.003); d blood glucose (p=0.024), 231 
systolic blood pressure (p=0.040). 232 
 233 
 234 
 235 
 236 
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Discussion 237 
This multi-center cohort study indicates no significant differences regarding functional outcome 238 
after IVT in normal weight patients compared to overweight, obese and underweight patients. Likewise, 239 
we found a similar risk of mortality and sICH for each BMI group.  240 
Obesity has become a medical and socio-economic burden with epidemic proportions and is an established 241 
risk factor for the incidence of stroke especially in younger patients. Recent studies surprisingly indicate 242 
better functional outcome and less mortality rates in stroke patients with excess of body weight as compared 243 
to their normal weight counterparts (“obesity paradox”) [4]. Data regarding impact of body weight on 244 
outcome after IVT are scarce and showed contradictory results hitherto. Sarikaya et al. reported 245 
significantly higher rates of mortality and unfavorable outcome in 53 obese patients as compared to 251 246 
non-obese patients (BMI <30 kg/m2), but stated the small size of study cohort study hindering a 247 
generalization of the findings and called for larger studies [16]. Seet et al. observed in their study on 169 248 
patients similar rates of functional recovery among obese (n=54), overweight, and normal weight patients 249 
after IVT [17]. In the study by Seo et al. assessing 321 Korean patients treated with IVT, being underweight 250 
was independently associated with poorer long-term survival as compared to patients with normal body 251 
weight [18]. The present IVT study included more patients than all 3 abovementioned studies together 252 
[17,19] and found no evidence for different clinical outcomes among normal weight, underweight, 253 
overweight or obese stroke patients. Moreover, we did not observe a difference in outcomes by comparing 254 
obese vs. non-obese patients, neither for clinical recovery nor for mortality. In addition, we also assessed 255 
clinical outcomes in severely obese patients (BMI > 35 kg/m2) separately, but the outcomes were still 256 
comparable to normal weight patients. Subsequently, we performed multivariate analyses correcting for 257 
potential outcome confounders, but failed to show an association between clinical endpoints and BMI. The 258 
same was also true for the risk of sICH, which was not associated with overweight or obesity. Furthermore, 259 
we assessed early neurological improvement at 24 hours post-treatment (defined as NIHSS score 260 
improvement by ≥ 40% from baseline) as a predictor of recanalization after thrombolysis and again did not 261 
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find significant differences among the 5 body weight groups. In line with this, the rates of both good clinical 262 
outcome (defined as mRS 0 and 1) and favorable clinical outcome (defined as mRS 0 to 2) at 3 months 263 
were similarly distributed among the cohorts. Unfortunately, data about radiological recanalization were 264 
too sparsely available for a firm analysis.  265 
The number of included patients were appropriate in normal weight, overweight and obese groups (n=321, 266 
378 and 175, respectively), but probably too low in underweight group (n=22). Thus, results for the latter 267 
body weight group need a cautious interpretation with respect to broad confidence intervals in outcome 268 
analyses for this group. Further studies are needed for outcome analyses in these patients, because severe 269 
underweight has been shown to be an independent risk factor for intracranial hemorrhages, poor clinical 270 
outcome and mortality in acute stroke [20–22]. Underweight is also a main indicator of malnutrition, which 271 
has a high prevalence among older patients and significant association with medical complications such as 272 
renal insufficiency. Lower glomerular filtration has been suggested to be a better risk indicator for sICH 273 
than age in stroke patients treated with IVT [23]. 274 
Overall, our data consistently indicate that BMI has no influence on clinical recovery and mortality in 275 
patients undergoing IVT for acute ischemic stroke. This finding is of clinical relevance as it indicates that 276 
the current weight-adapted dose regimen for IV alteplase as used in daily clinical routine is also appropriate 277 
for obese and severely obese patients. Furthermore, our data contradict the popular thesis of “obesity 278 
paradox”, which may be an obstacle against weight reduction in obese patients due to false assumptions 279 
(such as beneficial effect of obesity for stroke prevention). Several reasons may contribute to these 280 
discrepant observations. First, we strictly assessed acute stroke patients treated with IVT with pre-defined 281 
outcome analyses at 3 months. In other studies, the frequency of patients treated with thrombolysis was 282 
very low or not reported, whereas the follow-up duration ranged from 1 week to 10 years [2,24]. Data in 283 
our study were collected prospectively and in a structured way by trained stroke physicians allowing good 284 
data quality, whereas data collection was poorly described in other studies or data were derived from 285 
national healthcare databases [3,25] As consequence, many studies were not able to correct for relevant 286 
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outcome predictors such as stroke severity due to data lack of data [2,3,25,26]. Of note, obese stroke patients 287 
tend to be younger with lower stroke severity due to higher proportion of lacunar infarcts, which may 288 
explain better clinical outcomes in aforementioned studies (selection bias). Thus, the inverse association 289 
between BMI and mortality (obesity paradox) disappeared after correcting for stroke severity in some 290 
studies. [27,28]. Treatment bias may be another cause of obesity paradox as it has been shown that 291 
physicians treat obese patients more aggressively than lean patients due to assumed increase of vascular 292 
risk [29]. Publication bias may be a further reason for obesity paradox.  293 
Strengths of our study include (i) the relatively large cohort size of stroke patients addressing the influence 294 
of body weight on outcome after IVT, (ii) good quality of clinical data due to prospective and standardized 295 
assessments, (iii) separate analysis of all BMI groups from underweight to severely obese patients, and (iv) 296 
the use of comprehensive outcome parameters including early neurological improvement at 24 hours as a 297 
predictor for recanalization. 298 
Nevertheless, several limitations of our study have to be considered: (i) BMI has been criticized for its low 299 
accuracy in measuring obesity especially in older people, while waist-to-hip ratio or waist circumference 300 
may be more precise for this purpose [30]. (ii) This is an observational study, thus cautious interpretation 301 
is needed especially with respect to causality. To date, randomized controlled trials are lacking in this field. 302 
(iii) Body weight or body height were estimated by relatives or nurses in a subgroup of patients, although 303 
recent studies indicate that estimated weights to be similar to real values [31]. (iv) Because of the limited 304 
numbers of underweight and severely obese patients in our study, results concerning these groups should 305 
be interpreted with caution.  306 
 307 
Conclusion 308 
In this study, BMI was not associated with clinical outcomes, risk of sICH or with early neurological 309 
improvement after IVT. Our data suggest that the current weight-adapted dosage scheme of alteplase is 310 
appropriate for different body weight groups and challenge the existence of obesity paradox after stroke. 311 
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Supporting Information 387 
S1 Table. Baseline characteristics according to BMI categories. BMI categories were adopted according 388 
to World Health Organization (WHO) guidelines as follows: <18.5 kg/m2 for underweight, 18.5 to 24.9 389 
kg/m2 for normal weight, 25.0 to 29.9 kg/m2 for overweight, 30.0 to 34.9 kg/m2 for obesity and ≥35 kg/m2 390 
for severe obesity. Body weight groups showed unequal distributions for gender (higher percentage of 391 
females in the underweight group), as well as for hypertension and diabetes (higher prevalence in the excess 392 
body weight groups). Obese and severely obese patients had increased levels of blood glucose and were 393 
more often prescribed antithrombotic drugs. The initial impairment on admission was slightly lower in the 394 
high weight groups. Abbreviations: BMI (body mass index), IQR (inter quartile range), NIHSS (National 395 
Institute of Health Stroke Scale), CHD (coronary heart disease). 396 
 397 
S2 Table. Patient numbers and study periods for each individual center. 398 
 399 
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